The p53-dependent RR small subunit (p53R2) protein, a newly identified member of the ribonucleotide reductase family, plays a key role in the p53-dependent cellular response to DNA. Several recent studies have suggested that p53R2 also plays an important role in suppressing the invasive potential of human cancer cells. However, the cellular mechanism that regulates invasiveness remains largely unknown. In this study, we show that p53R2 interacts with MEK2 (extracellular signal-regulated kinase (ERK) kinase 2-mitogen-activated protein kinase (MAPK) kinase 2), the molecule immediately upstream of ERK in the Ras-Raf-MAPK signaling cascade. In co-immunoprecipitation and immunofluorescence analyses, we found that p53R2 and MEK2 interact physically in cultured mammalian cells, and that the p53R2 segment comprising amino acids 161-206 is critical for this interaction. Moreover, serum-induced phosphorylation of MEK1/2 and ERK1/2 was greatly augmented in human cancer cells expressing small-interfering RNA against p53R2. On the other hand, phosphorylation of MEK1/2 and ERK1/2 in human cancer cells was markedly attenuated by overexpression of p53R2. Furthermore, MEK2 was required for p53R2 knockdown-induced enhancement of the invasive ability and anchorageindependent growth of human lung cancer H1299 cells. Taken together, these findings show that p53R2 negatively modulates serum-induced MEK-ERK activity and inhibits the MEK-ERK-mediated malignancy potential of human cancer cells.
Introduction
Ribonucleotide reductase (RR) catalyzes de novo synthesis of deoxyribonucleotides from the corresponding ribonucleotides, providing a balanced supply of deoxyribonucleoside triphosphates (dNTPs) for DNA synthesis and repair (Nordlund and Reichard, 2006) . Mammalian RR is a multimeric enzyme comprising the large R1 subunit and the small R2 subunit. The level of R2 protein is low in the G1 phase of the cell cycle, but it increases to a maximum level during the S phase, whereas the level of R1 protein remains high and almost constant throughout the cell cycle. Therefore, the cell cycle-dependent activity of RR is controlled by the synthesis and degradation of R2. The recently identified p53-dependent RR small subunit (p53R2) functions as a catalytic partner of R1 (the regulatory subunit) to supply nucleotides for DNA repair (Nakano et al., 2000; Tanaka et al., 2000; Yamaguchi et al., 2001) . The 351 amino acid, p53R2, is 80% similar in sequence to R2, but it lacks its 33 amino-terminal residues, including the KEN box required for degradation during mitosis by anaphase-promoting complex Cdh1-mediated proteolysis; thus, p53R2 is present in G0/G1 cells (Chabes et al., 2003) .
The R1 and R2 subunits seem to play an additional role in determining the malignant potential of tumor cells. The expression of R1 suppresses tumor cell transformation, tumorigenesis and metastasis (Fan et al., 1997; Cao et al., 2003) , whereas the expression of R2 enhances the invasive potential of human and mouse cells (Fan et al., 1996; Zhou et al., 1998) . Interestingly, recent studies of highly invasive cancer cells have shown decreased levels of p53R2 and increased levels of R2 . Overexpression of p53R2 reduces migration and invasion of cancer cells . Therefore, in contrast to R2, p53R2 might function in the suppression of cancer cell invasion and metastasis, although the mechanism of this suppression remains to be determined.
In this study, we determined that MEK2 (extracellular signal-regulated kinase (ERK) kinase 2-mitogen-activated protein kinase (MAPK) kinase 2) is a binding partner of p53R2. In our experiments, p53R2 knockdown markedly increased serum-stimulated phosphorylation of MEK1/2 and ERK1/2, and p53R2 inhibited ERK1/2 phosphorylation by suppressing MEK2 activity. Our results suggest that p53R2 regulates the invasive potential of human lung cancer H1299 cells by modulating MEK2 activity.
Results

p53R2 binds to MEK2 in vivo
To identify proteins binding to p53R2, particularly those that might be involved in cancer progression, a yeast two-hybrid screen of an adult human liver cDNA library was performed using a pGBT9-p53R2 fusion protein as the bait. Screening of 2 Â 10 6 co-transformants identified eight positive clones that could be shown by rescreening to interact specifically with the p53R2 bait. Of these eight interactors, three were partial-length cDNAs of ERK2.
To determine whether MEK2 would interact with p53R2 in a cell endogenously expressing both proteins, we used immunoprecipitation assays. After U2OS cells were serum-starved for 16 h and incubated with or without 20% fetal bovine serum (FBS) for 30 min, the cells were lysed, and the cellular proteins were immunoprecipitated with a p53R2-specific antibody and subjected to western blotting with anti-MEK2 antibody. Immunoprecipitation with anti-p53R2 antibody showed that endogenous p53R2 bound to MEK2, and stimulation with 20% FBS did not significantly change the amount of p53R2 that bound to MEK2 (Figure 1a ), suggesting that p53R2 binding to MEK2 is constitutive and independent of MEK phosphorylation.
In a reciprocal co-immunoprecipitation assay, HEK293T cells were transiently transfected with an expression vector for full-length p53R2-GFP. The cell lysates were immunoprecipitated with anti-MEK2 antibody. As shown in Figure 1b , endogenous MEK2 was readily immunoprecipitated with the GFP-specific antibody (lane 4), but not with a control antibody (lane 5). Next, to determine the site of endogenous p53R2 and MEK2 localization in cells, we used immunofluorescence staining. As shown in Figure 1c , MEK2 and p53R2 were colocalized in the cytoplasms of U2OS and H1299 cells.
MEK1 and MEK2 are threonine/tyrosine kinases with both isoforms having the ability to phosphorylate and activate ERK1/2 (Yoon and Seger, 2006) . MEK1 and MEK2 show high homology only in their kinase domains. The N-termini and the characteristic prolinerich inserts, which contribute to the interaction of MEK1/2 with their activators and substrates are quite divergent (40% identity) (Kolch, 2000; Enslen and Davis, 2001 ). As p53R2 is interacted with MEK2, we investigated whether p53R2 also binds to MEK1 in cells. To ascertain whether endogenous MEK1 interacts with p53R2 in cells, HEK293T cells were transiently transfected with an expression vector for full-length p53R2-GFP. Immunoprecipitating lysates with anti-MEK1 antibody showed that endogenous MEK1 bound p53R2 (Figure 1d ).
To define the region of p53R2 that is necessary for MEK2 binding, we framed expression constructs encoding various GFP-tagged p53R2 deletion mutants. After HEK293T cells were transiently transfected with the constructs, MEK2 was immunoprecipitated with anti-MEK2 antibody, and the co-immunoprecipitates were then immunoblotted with anti-GFP antibody. p53R2 mutants containing the N-terminal 1-206 (DC2) interacted with MEK2, whereas the deletion of p53R2 residues 161-206 (DC1, DN2 and DN3) abolished the binding of p53R2 to MEK2 (Figure 2 ). These results suggested that amino acid segment 161-206 of p53R2 is important for its binding to MEK2.
p53R2 modulates serum-stimulated MEK1/2 phosphorylation To determine whether the binding of p53R2 to MEK2 affects MEK phosphorylation and activation, we examined serum-stimulated phosphorylation of MEK2 in cells expressing various levels of p53R2. When p53R2 small-interference RNA (siRNA) was transfected into U2OS and H1299 cells, the endogenous p53R2 protein level was knocked down by B90%, as shown by western blotting (Figure 3a) . We used these cells to analyze the effects of p53R2 knockdown on serum-stimulated MEK activation, which normally occurs through the phosphorylation of MEK residues, Ser-217 and Ser-221. The U2OS and H1299 cells were serum-starved for 16 h and then stimulated with 20% FBS for 10-30 min, respectively. In these conditions, serum-induced phosphorylation of MEK1/2 was only marginally increased in control siRNA-transfected cells. However, in p53R2 siRNA-transfected cells, MEK1/2 phosphorylation was increased significantly after serum stimulation ( Figures  3a and b) .
We next analyzed serum-induced MEK1/2 activation in U2OS and H1299 cells expressing p53R2. To perform this experiment, control and p53R2 expression of vector-transfected cells were incubated with 20% FBS medium for 24 h to fully activate MEK1/2. We observed that MEK1/2 was highly phosphorylated in vectortransfected cells 24 h after serum addition. As we expected, the induction of phospho-MEK1/2 by serum was significantly suppressed in U2OS and H1299 cells expressing p53R2s (Figures 3c and d) .
p53R2 regulates ERK1/2 activation by MEK2 As MEK can phosphorylate serine, threonine and tyrosine residues of its ERK1/2 substrate (Dhillon et al., 2007) , we next analyzed the effect of p53R2 on ERK activity in U2OS and H1299 cells. The activity of ERK1/2 was monitored in cells by measuring serumstimulated changes in ERK1/2 phosphorylation. U2OS and H1299 cells transfected with control or p53R2 siRNA were starved for 16 h and then stimulated with 20% FBS. Lysates were immunoblotted with an antibody specific for Thr-202/Tyr-204-phosphorylated ERK1/2. Time-course analysis showed that seruminduced phosphorylation of ERK1/2 in control U2OS cells reached a maximum at 30 min, whereas no significantly increasing phosphorylation of ERK1/2 in control H1299 cells occurred for 30 min (Figures 4a and b) . However, the downregulation of p53R2 significantly increased the stimulatory effect of serum on ERK1/2 phosphorylation, and phosphorylation of ERK1/2 was increased at 10 min in U2OS cells and at 30 min in H1299 cells. In contrast to our results regarding the ERK pathway, the downregulation of p53R2 did not affect the induction of Akt phosphorylation by serum, suggesting that p53R2 specifically modulates the MEK-ERK signaling pathway.
The effect of p53R2 on serum-stimulated ERK activity was next investigated in p53R2-overexpressing or control U2OS and H1299 cells. The cells were incubated with 20% FBS for 24 h to highly induce ERK1/2 phosphorylation, and the relative amounts of phospho-ERK1/2 in these cells were determined by probing blots with an antibody specific for Thr-202/Tyr-204-phosphorylated ERK1/2. As shown in Figures 4c and d , ERK1/2 phosphorylation in the cells expressing p53R2 was 40-60% lower than in the vector-transfected cells.
To confirm that the p53R2-modulated activation of MEK1 and MEK2 contributes to the activation of ERK by serum stimulation, MEK1-and MEK2-targeted siRNAs were transfected into p53R2-knockdown U2OS and H1299 cells, and the cells were starved for 16 h and then stimulated with 20% FBS for 10 (U2OS) or 30 min (H1299). Lysates were immunoblotted with an antibody specific for Thr-202/Tyr-204-phosphorylated ERK1/2. As shown in Figures 5a and b , serum-induced ERK1/2 phosphorylation was significantly suppressed in those p53R2-knockdown cells with reduced levels of endogenous MEK2 (Figures 5a and b) . These results indicate that p53R2 suppresses the ability of MEK2 to activate ERK1/2.
In contrast, MEK1 siRNA had only a slight or little effect on the suppression of ERK1/2 phosphorylation in p53R2-knockdown cells in response to serum stimulation. As endogenous p53R2 did not bind to MEK1, mapping analysis showed that MEK1 is much weaker than MEK2 in binding p53R2 constructs (data not shown), indicating that p53R2 may not significantly affect MEK1 function, because the MEK1-p53R2 interaction may be much weaker than the MEK2-p53R2 interaction. p53R2 decreases the invasive potential of H1299 cells by blocking MEK2 activity The MEK-ERK pathway is critical for cell migration and invasion in various types of cancer cells (Reddy et al., 2003) . Thus, the p53R2-mediated suppression of the MEK-ERK signaling pathway might be important for p53R2-mediated inhibition of tumor invasion. To determine whether p53R2 suppresses cancer cell invasion by inhibiting MEK activation, we used H1299 cells stably transfected with a p53R2 expression plasmid, with p53R2 siRNA, or a control plasmid. We confirmed that the level of p53R2 transcripts was markedly reduced in p53R2 siRNA-transfected cells ( Figure 6a ) and was markedly increased in p53R2-overexpressing cells (Figure 6b) , compared with the level in mock and control vector-transfected cells, respectively.
To investigate the potential inhibitory effects of p53R2 on H1299 cell invasion, we performed an in vitro invasion assay using 24-well trans-well units with polycarbonate filters coated on the upper side with Matrigel (BD BioSciences Discovery Labware, Bedford, MA, USA). Quantitation of invasive cells found on the lower surfaces of the inserts after 48 h showed that p53R2-silenced cells were much more invasive than control siRNA-transfected cells. In addition, overexpression of p53R2 significantly decreased cell invasiveness (Figure 6c ).
If p53R2 binding of MEK2 is required for the inhibition of invasion, then knockdown of MEK2 should decrease the invasive potential of p53R2-depleted cells. Thus, p53R2-knockdown H1299 cells were transfected with either control or MEK2-targeted siRNA and assessed for their invasive ability. The downregulation of MEK2 significantly decreased the invasive potential of p53R2-knockdown H1299 cells compared with that of control cells (Figure 6d ). The number of cells that crossed the Matrigel barrier to the lower surface of the insert was B2.6-fold lower in the MEK siRNA-transfected cells than in the control siRNA-transfected cells. Thus, on the basis of the effect of MEK2 siRNA, we conclude that p53R2 blocks invasion by suppressing the MEK signaling pathway.
p53R2 decreases the anchorage-independent H1299 cell growth by inhibition of MEK2 activity. We next sought to determine the effect of p53R2 on the anchorageindependent growth of H1299 cells. We used H1299 cells stably transfected with a p53R2 expression plasmid, with p53R2 siRNA, or a control plasmid to examine whether an increase or decrease in the p53R2 expression modulates anchorage-independent tumor growth in soft agar. Indeed, colony formation in p53R2 expressing Mapping regions of p53-dependent RR small subunit (p53R2) that interact with extracellular signal-regulated kinase kinase 2-mitogen-activated protein kinase kinase 2 (MEK2). Lysates of HEK293T cells expressing GFP-p53R2 (p53R2 wt) or p53R2 deletion mutants (DC1-DN3) were subjected to immunoprecipitation with anti-MEK2, and the lysates and resulting precipitates were subjected to immunoblot analysis with anti-GFP or anti-MEK2 antibodies. The asterisks indicate the immunoglobulin G (IgG) heavy chain, and the arrows show the p53R3 and its deletion mutants. The abilities of p53R2 and its deletions to interact with MEK2 were shown as ' þ ' or 'À'.
P53R2 modulates MEK-ERK activity C Piao et al H1299 cells was significantly inhibited compared with vector-transfected cells (Figure 7a ). The size and density of anchorage-independent colonies of p53R2 expressing H1299 cells were much lower than in control cells. In addition, p53R2 knockdown increased anchorageindependent growth in H1299 cells. Moreover, the downregulation of MEK2 markedly decreased anchorage-independent growth in p53R2-knockdown H1299 cells compared with control siRNA-transfected cells (Figure 7b ). Thus, these results support the notion that p53R2 suppresses the oncogenic potential of H1299 cells, and the suppression of MEK2 activity might contribute to the p53R2-mediated inhibition of anchorage-independent H1299 cell growth.
Discussion
Human RR consists of three subunits, R1, R2 and p53R2. R1 is a large peptide chain that contributes to the reduction of substrate, and small subunit R2 is essential for enzymatic activity (Nordlund and Reichard, 2006) . p53R2 gene contains a p53-binding sequence and can functionally substitute for R2 (Tanaka et al., 2000) . R1 interacts with either R2 or p53R2 to become the catalytically active form of eukaryotic RR. The R1-R2 complex provides deoxynucleotide triphosphate pools for normal DNA replication in proliferating cells. p53R2 is a p53-inducible RR and participates in p53-induced DNA repair by supplying dNTP in response to various types of DNA damage (Nakano et al., 2000; Tanaka et al., 2000; Hakansson et al., 2006) . The exact physiological function of p53R2 is not known, but it is essential for cell survival, because mice lacking functional p53R2 apparently grow normally up to 6 weeks but then die from kidney failure (Kimura et al., 2003; Powell et al., 2005) . In addition to being a component of the RR holoenzymes, R1, R2 and p53R2 subunits seem to play an important role in determining the malignant potential of tumor cells. Mouse R1 expression leads to a significantly reduced colony-forming ability in soft agar in oncogenic ras-transformed mouse fibroblast cells, whereas R1 anti-sense expression significantly increases anchorage-independent growth (Fan et al., 1997) . P53R2 modulates MEK-ERK activity C Piao et al R1 overexpression resulted in a decreased malignant potential of human colon cancer and ability of lung metastases (Gautam et al., 2003; Zheng et al., 2007) . Thus, it seems likely that R1 contains a malignancysuppressing activity. In contrast to R1, R2 has been proven to play a critical role in enhancing the malignant potential in human and mouse cells. The mouse R2 overexpression caused markedly increased the metastatic potential in BALB/c 3T3 and NIH3T3 cells (Fan et al., 1996) . Moreover, R2 cooperates with a variety of oncogenes to promote transformation and tumorigenesis (Fan et al., 1998) . This has been confirmed on the human KB cancer cells (Zhou et al., 1998) . As R1 and R2 expressions increase RR activities and expend dNTP pools (Fan et al., 1996 (Fan et al., , 1997 Zhou et al., 1998) , the opposing roles of R1 and R2 in malignancy is not related to their role in dNTP synthesis. p53R2 is a striking sequence homology to R2. However, p53R2 has been found to contain a malignancy-suppressing activity. For example, disruption of the p53-p53R2 DNA repair system was associated with colon tumorigenesis in ulcerative colitis (Yoshida et al., 2006) . p53R2 expression was negatively related to the metastasis of colon adenocarcinoma samples . Similarly, the decrease of p53R2 is associated with cell invasion potential, which was observed in both p53 wild-type KB (orophryngeal cancer) cells and p53 mutant PC-3 (prostate cancer), as well as in Mia PaCa-2 (pancreatic cancer) cells . Moreover, overexpression of p53R2 decreased the cellular invasion potential in KB and PC-3 cells, whereas knockdown of p53R2 by siRNA resulted in a threefold increase in cell migration . A recent study showed that recombinant R2 protein increases the radical generation and the formation of reactive oxygen species (ROS), whereas p53R2 has an antioxidant activity . ROS are produced as a by-product of cellular metabolism and P53R2 modulates MEK-ERK activity C Piao et al exposure to ultraviolet rays, ionizing radiation and environmental carcinogens (Barnes and Lindahl, 2004) . ROS cause significant damage to DNA, including oxidized bases, abasic sites and strand breaks (Barnes and Lindahl, 2004) . These oxidative DNA lesions lead to spontaneous mutagenesis, resulting in various types of cellular dysfunctions, including cancer and cell death. ROS also have mitogenic effects and can play a direct role in neoplastic transformation (Droge, 2002) . Thus, p53R2 might have an inhibiting malignancy potential by eliminating ROS to maintain genomic integrity in response to oxidative stress and by avoiding the activation of ROS-induced mitogenic activity. Similarly, R2 might induce mutagenesis and tumorigenesis through ROS generation. However, the detailed mechanisms by which p53R2 and R2 affect malignancy potential are unknown. In this study, we used a yeast two-hybrid system to identify MEK2 as a p53R2-binding protein. This interaction also occurs in cultured human cancer cells, as shown by the co-immunoprecipitation and colocalization of endogenous MEK2 with p53R2. Endogenous 
P53R2 modulates MEK-ERK activity C Piao et al
MEK2 and p53R2 form a complex under the conditions of both serum starvation and serum stimulation. A common theme in growth factor signaling cascades is the induction of specific intracellular protein-protein interactions as a consequence of the activation of growth factor receptors. However, this model does not apply to the findings reported herein; although serum is a well-known activator of MEK-ERK, it did not alter the interaction between p53R2 and MEK2 in our experiments, suggesting that p53R2 binding to MEK2 is constitutive and independent of MEK phosphorylation. We also observed that p53R2 binds to MEK1 after transfection of the p53R2 construct. However, endogenous p53R2 did not bind to MEK1, and mapping analysis showed that MEK1 is much weaker than MEK2 in binding p53R2 constructs (data not shown).
MEK1 and MEK2 are threonine/tyrosine kinases with both isoforms having the ability to phosphorylate and activate ERK1 and ERK2. ERK, once activated by MEK, has numerous cytosolic and nuclear substrates (Widmann et al., 1999) . We have shown that changing the intracellular p53R2 protein level affected the phosphorylation of MEK1/2 and that of its downstream kinase, ERK1/2. Knockdown of p53R2 with siRNA markedly increased serum-induced phosphorylation of MEK1/2 and ERK1/2 in U2O2 and H1299 cells, and overexpression of p53R2 impaired the ability of serum to induce phosphorylation of MEK1/2 and ERK1/2. 
Notably, the downregulation of MEK2 in p53R2-depleted cells significantly inhibited serum-induced ERK1/2 phosphorylation, whereas MEK1 knockdown has only a marginal effect on the suppression of ERK1/2 phosphorylation, suggesting that p53R2 serves as a negative regulator of the MEK-ERK signaling pathway, and that the interaction between p53R2 and MEK2 might be important for modulating the activity of ERK1/2. The MAPKs comprise a family of proteins that mediate a series of distinct signaling cascades that are targeted by a multitude of extracellular stimuli (Dhillon et al., 2007) . Activated MAPKs translocate to the nucleus, in which they phosphorylate their target molecules, including various transcription factors. An activated MAPK pathway has been detected in many human tumors, suggesting that MAPK is involved in tumor progression and metastasis (Dhillon et al., 2007) . Among the major groups of MAPKs (JNK, p38 and ERK1/2), ERK signaling plays the major role in regulating the invasive and metastatic potential of various cancer cells (McCubrey et al., 2007) . ERK1/2 fosters increased transcription of genes encoding matrix metalloproteinases and urokinase plasminogen activator and its receptor. It can also promote invasiveness by reducing the transcription of tight junction proteins and of metastasis suppressor genes (Reddy et al., 2003) . In addition, the extranuclease activities of ERK1/2, including the activation of cell motility machinery and disruption of focal adhesions, may contribute to increased invasiveness. In this study, using MEK2-specific siRNA, we showed that p53R2 inhibits invasion and anchorage-independent growth by suppressing MEK activity. Therefore, we conclude that interference with MEK-ERK signaling accounts for the effect of p53R2 on tumor cell invasion and transformation, and that this effect is probably mediated by the blockage of the MEK-ERK activity and the resulting transcriptional activity. Interestingly, overexpression of R2 leads to increased MAPK-2 activity and is associated with the Ras-Raf-MAPK signaling pathway (Fan et al., 1998) . However, how R2 subunits regulate the MAPK activity remains largely unknown. Therefore, it is possible that R2 activates the MAPK signaling pathway by the association of R2 with MEK2, resulting in the enhancement of malignancy and metastatic potential. Accordingly, this possibility is currently under investigation.
Recently, Xu et al. (2008) reported that R2 and p53R2, but not R1, transgenic mice showed spontaneous lung neoplasm. Lung tumor induction in R2 and p53R2 transgenic mice might be independent of RR enzyme activity, because R1 transgenic mice did not result in any overt spontaneous phenotype (Gautam and Bepler, 2006) . Surprisingly, Xu et al. (2008) showed that NIH3T3 cells stably transfected with p53R2 show an P53R2 modulates MEK-ERK activity C Piao et al increased mutation frequency. However, earlier results have shown that p53R2 has a pivotal role in the repair of DNA damage caused by exposure to various genotoxins. For example, inhibition of endogenous p53R2 expression reduced RR activity and DNA repair after DNA damage in a p53-dependent manner (Tanaka et al., 2000) . p53 and p21 by binding to p53R2 help in supplying dNTP for DNA repair (Xue et al., 2003 . Knockdown of p53R2 by siRNA impairs DNA repair in LNCaP cells (Devlin et al., 2008) , and the suppression of p53R2 gene expression resulted in a significant increase in ionizing radiation-induced mutagenesis in human lymphoblastoid TK6 cells (Tsai et al., 2006) . Interestingly, overexpression of thymidine synthetase, another enzyme involved in dNTP biosynthesis, transformed cultured cells (Rahman et al., 2004) and promoted tumor formation in transgenic mice . As abnormal nucleotide levels cause increased base misinsertion and decreased proof reading because of enhanced polymerization rate (Mathews, 2006) , overexpression of p53R2 might lead to alterations in dNTP levels, resulting in impaired replication fidelity and might also trigger mutation rate during DNA replication. Thus, although p53R2 plays an important role in p53-dependent DNA repair to prevent mutagenesis in response to DNA damage, p53R2 transgenic mice paradoxically showed high mutation rate, and this increased mutation rate in p53R2 transgenic mice might contribute to carcinogenic effects in vivo.
In summary, we identified a novel association between p53R2 and MEK2. This interaction was documented in cells independent of serum stimulation. We show that the specific knockdown of endogenous p53R2 significantly augmented serum-stimulated MEK-ERK activities, whereas overexpression of p53R2 inhibited MEK-ERK activities. We also show that by targeting MEK2 activity that, p53R2 inhibits ERK1/2 signaling, and consequently, prevents cancer cell invasion and transformation. An activated MAPK pathway has been detected in many human tumors, suggesting that MAPK is involved in tumor progression and metastasis. Thus, p53R2 might be involved in the suppression of oncogenic potential by inhibiting the MEK-ERK signaling pathway. Understanding the role of p53R2 in cellular transformation and invasion may provide a new strategy for inhibiting tumor development.
Materials and methods
Cell culture U2OS human osteosarcoma cells were cultured in McCoy's 5A medium (Cellgro, Herndon, VA, USA). H1299 human lung cancer cells were grown in RPMI 1640 (GIBCO, Grand Island, NY, USA) medium and HEK293T cells were grown in DMEM. Cultures were supplemented with 10% FBS and with 100 units/ml each of penicillin and streptomycin (Invitrogen, Carlsbad, CA, USA) and grown under a 5% CO 2 atmosphere at 37 1C. The HEK293T cell line was obtained from the Cornell Institute for Medical Research. All other cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA).
Preparation of constructs and clones
The cDNA for human p53R2 was amplified by RT-PCR (reverse transcriptase-PCR) from GM00637 human fibroblast cells using the p53R2 primers 5 0 -GAA TTC ATG GGC GAC CCG GAA AGG C -3 0 (sense) and 5 0 -AAA ATC TGC ATC CAA GGT GAA -3 0 (anti-sense). The amplified p53R2 cDNA construct was cloned into the mammalian expression vector, pcDNA3.1/V5-His TOPO (Invitrogen), and confirmed by DNA sequencing. The full-length p53R2 cDNA and various truncated p53R2 cDNA fragments (cDNA nts 1-480, 1-618, 91-1053, 619-1053 and 946-1053) were PCR-amplified using PCR Master Mix (Promega, Madison, WI, USA), and the resulting PCR products were cloned into pcDNA-DEST47 (Invitrogen). The p53R2 expression vector, and their control vectors were transfected into H1299 cells using LipofectA-MINE 2000 (Invitrogen) according to the manufacturer's instructions. After transfection, cells were incubated for 5 weeks in a complete medium containing 400 mg/ml G418, and the clones resistant to G418 were isolated and analyzed.
Yeast two-hybrid screening A yeast two-hybrid assay was performed according to the manufacturer's protocol (Clontech, Mountain View, CA, USA). Briefly, a pGBT9-derivative vector encoding p53R2 was transformed into the yeast strain, AH109, and transformants were selected. A PACT2-MEK2 plasmid was then transformed into the initial transformants, which were plated on SD/Trp 
Western blotting and immunoprecipitation
Western blot analysis was performed as described earlier using a goat polyclonal antibody against p53R2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), a mouse monoclonal antibody against p53R2 (Abnova, Taipei, Taiwan) and Abs against Akt, phospho-Akt, ERK1/2, phospho-ERK1/2, MEK1, MEK2, phospho-MEK1/2 and a-tubulin (Cell Signaling Technology, Danvers, MA, USA). For immunoprecipitation, whole cell lysates were prepared in lysis buffer (50 mM HEPES, pH 8.0, 150 mM NaCl, 0.5% Triton X-100 (Sigma, St Louis, MO, USA), 0.5% Nonidet P-40 (USB, Cleveland, OH, USA), 100 mM NaF, 1 mM PMSF, 1 mM DTT, 1 Â complete protease cocktail, 10% glycerol). After incubation for 1 h at 4 1C, cellular debris was removed by centrifugation at 14 000 Â g for 30 min. The cell lysates were immunoprecipitated using the indicated Abs and isotype-matched control Abs with protein A Sepharose (Amersham Pharmacia Biotech., Buckinghamshire, England, UK) for 4 h at 4 1C. The supernatant fraction was subjected to SDS-PAGE and immunoblotted with an antibody specific for MEK2, p53R2 or GFP. The images were obtained with LAS-4000 mini (Fuji, Tokyo, Japan).
Small-interference RNA Knockdown of p53R2 and MEK2 A siRNA targeting human p53R2 was designed using the siRNA Target Finder Program (Ambion, Austin, TX, USA). The sequence of the 21-bp p53R2 siRNA duplex was 5 0 -UGA GUU UGU AGC UGA CAG AUU-3 0 (sense strand). MEK2 and MEK1 siRNA were purchased from Cell Signaling Technology and control siRNA was from Bioneer (Daejeon, Korea). Cells were transiently transfected with siRNA duplexes using Lipofectamine RNAi MAX (Invitrogen) and stably transfected with an siRNA expression plasmid derived from the pSilence hygro vector (Ambion), which includes a human U6 promoter and a hygromycin resistance gene, using LipofectAMINE 2000 (Invitrogen). The pSilence hygro vector was used as a negative control. When necessary, colonies were selected on the basis of their resistance to 100 ml/ml hygromycin in the medium after transfection.
Immunofluorescence cytochemistry Cells grown on a cover slip were fixed with 4% paraformaldehyde in phosphate-buffered saline for 5 min at room temperature, permeabilized with 0.3% Triton X-100 in phosphate-buffered saline for 10 min and treated with 0.5% bovine serum albumin for 1 h at room temperature. The cultures were then stained with anti-MEK2 or anti-p53R2 antibody overnight at 4 1C. After washing to remove the excess primary antibody, the cultures were incubated for 1 h at room temperature with a fluorescence-conjugated secondary antibody (Alexa Fluor 488 chicken anti-rabbit IgG (immunoglobulin G) or Alexa Fluor 563 chicken anti-goat IgG; Molecular Probes, Eugene, OR, USA). Excess antibody was removed, and the cells were imaged using a confocal microscope (Zeiss LSM 510 Meta; Carl Zeiss, Jena, Germany).
Invasion assay
Cellular invasion was assayed in triplicate using a Matrigel Invasion Chamber (BD Biosciences Discovery Labware, Bedford, MA, USA). In this assay, 2 Â 10 5 H1299 transfectants were seeded in the upper chamber in serum-free media. For siRNA studies, cells were transfected with control siRNA or MEK2-targeted siRNA 48 h before seeding into the upper chamber. Complete medium containing 20% FBS served as a chemoattractant in the lower chamber. After 24 h, the invading cells on the lower membrane were stained and counted.
Anchorage-independent growth assay Cells (2 Â 10 4 ) were mixed with cell-specific medium in 0.3% agar, plated on top of a 0.5% agar base and covered with 10% FBS medium. Cultures were maintained at 37 1C in an incubator for 20 days. The medium was changed every 3 days, and the number of colonies in five random fields was counted.
Statistical analysis
Data represent the mean±s.d. Statistical comparisons were carried out using an unpaired t-test. **P-values o0.01 were considered significant. Abbreviations dNTP, deoxyribonucleoside triphosphate; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK2, ERK kinase 2-MAPK kinase 2; p53R2, p53-dependent RR small subunit; ROS, reactive oxygen species; RR, ribonucleotide reductase.
